VRTX vs MRNA vs REGN
161 measures in 16 categories, one definition each, computed from filings and market data.
VRTX76.1
Vertex Pharmaceuticals Incorporated
Healthcare · Biotechnology
$499.74 −1.77%$126.7B mkt cap
Score DNA
REGN68.4
Regeneron Pharmaceuticals, Inc.
Healthcare · Biotechnology
$790.74 −0.70%$81.4B mkt cap
Score DNA
Price, rebased to 100 three years ago
VRTX MRNA REGN · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | VRTX | MRNA | REGN |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 0 | 0 |
| Insider $ bought, 180d | — | — | — |
| Congress purchases, 180d | 2 | 3 | 2 |
| Last Congress purchase | 2026-09-04 | 2026-09-11 | 2026-07-07 |
| 13F net change in holders | +69 | +59 | −58 |
| ETFs adding shares, 30d | 1,628 | 940 | 1,460 |
| ETFs trimming, 30d | 1,374 | 635 | 1,358 |
| Net ETF funds, 30d | +254 | +305 | +102 |
Valuation
16 measures| Measure | VRTX | MRNA | REGN |
|---|---|---|---|
| P/E (TTM) | 28.8x
59th
|
— | 18.8x
51st
|
| PEG (P/E ÷ 3-yr EPS CAGR) | 2.86
89th
|
— | 7.83
100th
|
| Price / sales | 10.0x
57th
|
39.1x
86th
|
5.2x
28th
|
| Price / book | 6.3x
70th
|
12.9x
82nd
|
2.6x
25th
|
| Price / tangible book | 6.8x
62nd
|
4.2x
42nd
|
2.2x
12th
|
| Price / free cash flow | 33.4x
63rd
|
— | 23.1x
51st
|
| Price / operating cash flow | 29.5x
63rd
|
— | 18.3x
51st
|
| Enterprise value | $120.8B
100th
|
$83.2B
99th
|
$75.4B
99th
|
| EV / sales | 9.6x
60th
|
37.3x
86th
|
4.9x
36th
|
| EV / EBITDA | 22.0x
64th
|
— | 13.1x
38th
|
| EV / EBIT | 22.9x
55th
|
— | 14.4x
35th
|
| EV / free cash flow | 31.8x
63rd
|
— | 21.4x
51st
|
| Earnings yield | 3.5%
84th
|
-3.6%
57th
|
5.3%
86th
|
| FCF yield | 3.0%
81st
|
-1.4%
65th
|
4.3%
85th
|
| Operating cash flow yield | 3.4%
81st
|
-1.2%
64th
|
5.5%
85th
|
| Graham number (per share) | $175.20
92nd
|
— | $520.36
100th
|
Profitability (TTM)
12 measures| Measure | VRTX | MRNA | REGN |
|---|---|---|---|
| Gross margin | 86.0%
48th
|
-12.6%
5th
|
84.9%
47th
|
| EBITDA margin | 43.6%
91st
|
-127.0%
34th
|
37.0%
89th
|
| Operating margin | 38.6%
91st
|
-149.0%
34th
|
25.6%
84th
|
| EBIT margin | 41.8%
92nd
|
-137.8%
34th
|
33.6%
88th
|
| Net margin | 34.9%
89th
|
-141.4%
35th
|
27.9%
86th
|
| NOPAT margin | 32.2%
90th
|
-117.7%
35th
|
21.4%
82nd
|
| FCF margin | 30.1%
88th
|
-54.9%
48th
|
22.7%
84th
|
| Operating cash flow margin | 34.0%
88th
|
-47.2%
50th
|
28.6%
87th
|
| R&D / revenue | 31.4%
34th
|
129.1%
69th
|
41.6%
47th
|
| SG&A / revenue | 15.9%
4th
|
43.3%
32nd
|
17.7%
6th
|
| Stock comp / revenue | 5.5%
17th
|
10.1%
36th
|
6.4%
21st
|
| Effective tax rate | 16.5%
15th
|
21.0%
19th
|
16.2%
15th
|
Returns on capital
11 measures| Measure | VRTX | MRNA | REGN |
|---|---|---|---|
| ROE (on average equity) | 23.5%
87th
|
-39.0%
37th
|
14.0%
78th
|
| ROA | 17.1%
86th
|
-27.4%
36th
|
10.8%
82nd
|
| ROIC | 28.3%
62nd
|
-90.1%
24th
|
12.9%
56th
|
| ROCE | 22.5%
88th
|
-36.4%
29th
|
14.4%
83rd
|
| Return on tangible assets | 20.5%
88th
|
-26.7%
33rd
|
13.1%
82nd
|
| Cash ROIC (OCF / invested capital) | 29.9%
78th
|
-36.2%
42nd
|
17.3%
70th
|
| Gross profitability (GP / assets) | 39.6%
65th
|
-2.6%
3rd
|
31.6%
54th
|
| ROIC, 3-yr average | 17.0%
86th
|
-66.9%
40th
|
14.6%
82nd
|
| ROIC, 5-yr average | 31.9%
72nd
|
-23.1%
41st
|
22.0%
68th
|
| ROE, 5-yr average | 17.6%
95th
|
-8.5%
77th
|
17.9%
96th
|
| Incremental ROIC | 29.3%
59th
|
15.7%
51st
|
-38.9%
21st
|
Growth
17 measures| Measure | VRTX | MRNA | REGN |
|---|---|---|---|
| Revenue growth (TTM YoY) | 10.6%
41st
|
-27.2%
20th
|
9.3%
40th
|
| Revenue growth (QoQ) | 11.6%
44th
|
-62.7%
6th
|
19.0%
56th
|
| Revenue CAGR, 3 yr | 9.9%
35th
|
-40.5%
6th
|
7.0%
33rd
|
| Revenue CAGR, 5 yr | 13.6%
41st
|
-19.7%
8th
|
4.6%
26th
|
| Gross profit CAGR, 3 yr | 9.1%
37th
|
— | 7.2%
35th
|
| Operating income CAGR, 3 yr | 7.1%
29th
|
— | -4.5%
24th
|
| Net income growth (TTM YoY) | 21.1%
39th
|
— | -2.9%
26th
|
| Net income CAGR, 3 yr | 9.4%
38th
|
— | 0.2%
31st
|
| EPS growth (TTM YoY) | 22.6%
39th
|
— | -1.3%
26th
|
| EPS CAGR, 3 yr | 10.1%
38th
|
— | 2.4%
31st
|
| EPS CAGR, 5 yr | 17.7%
53rd
|
— | -6.3%
20th
|
| FCF growth (TTM YoY) | 8.5%
39th
|
— | -8.4%
14th
|
| FCF CAGR, 3 yr | -0.7%
12th
|
— | -5.3%
6th
|
| Operating cash flow CAGR, 3 yr | 1.8%
12th
|
— | -2.1%
6th
|
| Book value CAGR, 3 yr | 10.1%
69th
|
-27.3%
23rd
|
12.1%
70th
|
| Dividend CAGR, 3 yr | — | — | 29.4% |
| Sustainable growth rate | 23.5%
54th
|
— | 12.8%
23rd
|
Margin history & stability
7 measures| Measure | VRTX | MRNA | REGN |
|---|---|---|---|
| Gross margin, 3-yr average | 86.2%
56th
|
24.2%
12th
|
85.0%
54th
|
| Operating margin, 3-yr average | 23.2%
91st
|
-116.0%
51st
|
27.6%
95th
|
| Net margin, 3-yr average | 20.7%
89th
|
-117.6%
49th
|
30.4%
93rd
|
| FCF margin, 3-yr average | 15.8%
84th
|
-82.8%
53rd
|
24.5%
90th
|
| Revenue stability (0-1) | 0.99
97th
|
0.48
35th
|
0.87
77th
|
| Earnings stability (0-1) | 0.09
12th
|
0.46
55th
|
0.69
72nd
|
| Margin stability (0-1) | 0.99
94th
|
0.15
35th
|
0.99
96th
|
Liquidity (latest quarter)
7 measures| Measure | VRTX | MRNA | REGN |
|---|---|---|---|
| Cash & short-term investments | $7.9B
99th
|
$5.1B
98th
|
$8.0B
100th
|
| Net cash (− = net debt) | $5.9B
99th
|
$3.9B
96th
|
$6.0B
100th
|
| Working capital | $8.6B
99th
|
$3.3B
96th
|
$12.9B
100th
|
| Current ratio | 3.19
22nd
|
2.29
10th
|
3.34
25th
|
| Quick ratio | 2.74
19th
|
2.18
10th
|
2.78
21st
|
| Cash ratio (cash + ST investments / current liabilities) | 1.99
24th
|
2.03
24th
|
1.45
15th
|
| Defensive interval (days) | 609 days
62nd
|
629 days
64th
|
577 days
59th
|
Leverage & solvency (latest quarter)
13 measures| Measure | VRTX | MRNA | REGN |
|---|---|---|---|
| Total debt | $2.0B
95th
|
$1.3B
94th
|
$2.0B
96th
|
| Debt / equity | 0.10
42nd
|
0.19
54th
|
0.06
31st
|
| Net debt / equity | −0.29
72nd
|
−0.57
59th
|
−0.19
75th
|
| Debt / assets | 7.2%
37th
|
11.7%
48th
|
4.8%
27th
|
| Debt / capital | 8.9%
42nd
|
16.0%
54th
|
5.9%
31st
|
| Debt / EBITDA | 0.36
31st
|
— | 0.35
27th
|
| Net debt / EBITDA | −1.07
48th
|
— | −1.04
52nd
|
| Interest coverage (EBIT / interest) | 800.2x
98th
|
−122.8x
6th
|
94.2x
93rd
|
| Cash interest coverage | 650.4x
98th
|
−42.1x
11th
|
80.2x
91st
|
| Debt payback (years of OCF) | 0.5 yrs
39th
|
— | 0.4 yrs
34th
|
| Liabilities / assets | 26.2%
39th
|
38.3%
53rd
|
24.0%
36th
|
| IS credit model rating | AAA | BBB+ | AAA |
| Implied credit spread (bps) | 50
0th
|
225
46th
|
50
0th
|
Efficiency
11 measures| Measure | VRTX | MRNA | REGN |
|---|---|---|---|
| Asset turnover | 0.49
65th
|
0.19
40th
|
0.39
57th
|
| Fixed asset turnover | 3.79
44th
|
0.81
16th
|
2.85
37th
|
| Inventory turnover | 1.1
30th
|
9.6
90th
|
0.7
12th
|
| Receivables turnover | 6.3
52nd
|
84.1
97th
|
2.6
12th
|
| Days sales outstanding | 58 days
51st
|
4 days
8th
|
143 days
89th
|
| Days inventory outstanding | 338 days
70th
|
38 days
10th
|
488 days
88th
|
| Days payables outstanding | 90 days
38th
|
25 days
7th
|
146 days
46th
|
| Cash conversion cycle (days) | 306 days
87th
|
17 days
53rd
|
485 days
94th
|
| Capex / revenue | 3.9%
70th
|
7.7%
84th
|
5.9%
78th
|
| Capex / depreciation | 2.26
92nd
|
0.71
68th
|
1.74
85th
|
| Operating expense ratio | 47.9%
13th
|
597.9%
83rd
|
53.5%
18th
|
Cash flow & earnings quality
7 measures| Measure | VRTX | MRNA | REGN |
|---|---|---|---|
| Operating cash flow / net income | 0.97
41st
|
— | 1.03
43rd
|
| FCF / net income | 0.86
46th
|
— | 0.81
41st
|
| FCF / operating cash flow | 88.4%
33rd
|
— | 79.3%
18th
|
| Capex / operating cash flow | 11.6%
67th
|
— | 20.7%
82nd
|
| Accruals ratio | 0.4%
74th
|
-18.3%
12th
|
-0.3%
71st
|
| Sloan accruals ratio | 8.1%
56th
|
-13.6%
17th
|
-2.0%
32nd
|
| Earnings quality score (0-1) | 0.75
38th
|
— | 1.00
81st
|
Scores & forensic checks
15 measures| Measure | VRTX | MRNA | REGN |
|---|---|---|---|
| IS score | 76
93rd
|
30
36th
|
68
84th
|
| IS profitability | 96
93rd
|
11
4th
|
82
89th
|
| IS growth | 64
53rd
|
24
15th
|
45
27th
|
| IS value | 44
79th
|
36
51st
|
69
93rd
|
| IS momentum | 80
87th
|
30
14th
|
67
57th
|
| IS risk (safety) | 100
52nd
|
100
52nd
|
100
52nd
|
| IS quality | 86
94th
|
41
32nd
|
85
93rd
|
| IS balance sheet | 97
99th
|
0
0th
|
97
98th
|
| IS earnings quality | 75
95th
|
41
36th
|
68
85th
|
| IS cash flow | 80
90th
|
30
8th
|
69
83rd
|
| Piotroski F-score (0-9) | 6
77th
|
2
4th
|
7
89th
|
| Altman Z-score | 12.9
81st
|
4.3
54th
|
6.4
67th
|
| Beneish M-score | −2.37
49th
|
−4.42
9th
|
−2.31
51st
|
| Ohlson O-score | −11.47
7th
|
−7.37
35th
|
−11.29
7th
|
| IS credit score | 97
96th
|
62
46th
|
97
96th
|
Size (TTM)
8 measures| Measure | VRTX | MRNA | REGN |
|---|---|---|---|
| Market cap | $126.7B
100th
|
$87.0B
99th
|
$81.4B
99th
|
| Revenue | $12.6B
99th
|
$2.2B
90th
|
$15.5B
100th
|
| EBITDA | $5.5B
99th
|
−$2.8B
0th
|
$5.8B
100th
|
| Net income | $4.4B
100th
|
−$3.2B
0th
|
$4.3B
99th
|
| Free cash flow | $3.8B
100th
|
−$1.2B
0th
|
$3.5B
99th
|
| Total assets | $27.4B
99th
|
$11.0B
96th
|
$41.7B
100th
|
| Shareholders' equity | $20.2B
99th
|
$6.8B
98th
|
$31.7B
100th
|
| Employees | 6,400
98th
|
4,700
97th
|
15,410
100th
|
Price performance
9 measures| Measure | VRTX | MRNA | REGN |
|---|---|---|---|
| 1 day | −1.8% | −7.8% | −0.7% |
| 1 week | −2.0% | −3.1% | +5.9% |
| 1 month | −3.2% | +37.9% | +0.2% |
| 3 months | +4.0% | +266.5% | +17.6% |
| 6 months | +13.3% | +305.8% | +5.3% |
| Year to date | +10.5% | +419.7% | +2.0% |
| 1 year | +22.5% | +796.8% | +37.4% |
| 3 years, cumulative | +36.8% | +101.4% | −4.9% |
| 5 years, cumulative | +179.3% | −45.2% | +44.6% |
Technicals
4 measures| Measure | VRTX | MRNA | REGN |
|---|---|---|---|
| RSI 14 | 43.8 | 61.7 | 57.2 |
| From 52-week high | −10.8% | −10.0% | −8.0% |
| From 52-week low | +24.0% | +878.5% | +40.4% |
| Beta | 0.32 | 0.90 | 0.24 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17